As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.
Novo Nordisk has told the world it expects patients to lose “at least 25%” of their body weight on its experimental drug ...
Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy ...
Novo Nordisk's new weight-loss drug, CagriSema, missed the company's target in Phase 3 trials, causing a 20.37% drop in ...
Eli Lilly strikes Zepbound deal with the telehealth platform Ro, amid questions about future of compounded GLP-1s.
Although the GLP-1 drug Zepbound has been shown to be effective in promoting weight loss, availability and price have been ...
Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, ...
It is made possible through a first-of-a-kind integration with Eli Lilly’s direct-to-consumer website, and aims to streamline ...
Eli Lilly said its drug Zepbound led to greater weight reduction than rival Novo Nordisk's Wegovy in a head-to-head ...
The Associated Press on MSN14d
Eli Lilly invests $3B to expand Wisconsin factory to help meet demand for Mounjaro, ZepboundCopyright 2024 The Associated Press. All Rights Reserved. David Ricks, chair and CEO of Eli Lilly, fields a question ...
Zepbound is the “superior” choice for people looking to shed a few pounds, at least compared to Novo Nordisk’s (NVO) Wegovy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback